Dr. Sarah Goldberg is an Associate Professor of Medicine at Yale School of Medicine and Yale Cancer Center. She is a medical oncologist who treats patients with thoracic malignancies and performs clinical and translational research on lung cancer.

Dr. Gettinger is internationally recognized for his expertise in lung cancer treatment and research. He is best known for his work in immunotherapy and targeted therapy for non-small cell lung cancer. He currently leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary translational research interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies.

Dr. Gerber is Professor of Internal Medicine and Population & Data Sciences at UT Southwestern Medical Center. Within the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, Dr. Gerber serves as Associate Director of Clinical Research.

Dr. Gentzler is a thoracic medical oncologist and Associate Professor at the University of Virginia Cancer Center. He is a clinical investigator and active participant in several cooperative groups, including the ECOG-ACRIN Cancer Research Group, the NCI ETCTN, and the Hoosier Cancer Research Network (HCRN). He is currently the Director of Thoracic Medical Oncology Clinical Research at the University of Virginia chair of the Cancer Center Lung Cancer Translational Research Team and Protocol Review Committee (PRC).

Professor Edward Garon is Director of Thoracic Oncology at the David Geffen School of Medicine at UCLA and the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He has been the lead investigator of clinical trials that have led to multiple drug approvals and approval of a companion diagnostic. He has received funding from multiple peer reviewed funding agencies including the National Cancer Institute.

Dr. Justin Gainor is Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, Co-Leader of the DF/Harvard Cancer Center Lung Cancer Program, and Assistant Professor of Medicine at Harvard Medical School. Dr. Gainor received his undergraduate degree from Johns Hopkins University and medical degree from Harvard Medical School. He completed residency training at the Massachusetts General Hospital and medical oncology fellowship in the combined Dana-Farber/Partners Cancer Care Program. He joined the faculty of Massachusetts General Hospital and Harvard Medical School in 2013. His major research interests have centered around two themes: targeted therapy and immunotherapy. He is the principal investigator of multiple clinical trials evaluating novel targeted therapies among patients with oncogene-driven lung cancers, with a particular focus on oncogenic fusions involving anaplastic lymphoma kinase (ALK) and RET. Complementing these efforts, he also led efforts to define the molecular mechanisms of resistance to targeted therapies. Recently, he worked to transfer the same clinical-translational research framework pioneered in targeted therapies to the immunotherapy setting. He is a currently co-leader of the SU2C/AACR/ACS Lung Cancer Dream Team/Mark Foundation EXTOL Team.

I am the Chief of Division of Hematology/Oncology at Henry Ford Cancer Institute/Henry Ford Health System.. I am a medical oncologist by training and my area of interest is lung cancer research in general and drug development in lung cancer, in particular. I have conducted and participated in many lung cancer specific trials and in phase I trials, including investigator initiated trials based on laboratory research. I have also been a principal investigator of a Southwest Oncology Group trial, S0528 and NCI protocol 7389. Currently I am a PI of several ongoing trials, including national PI for S1507. I have also engaged in many epidemiologic studies in the field of lung cancer, publishing on features of lung cancer in African-Americans and in young patients. I have served as one of the PIs of multi-PI R21 to identify ‘driver’ genetic alterations in African-American lung cancer patients. I served as the co-leader of the Molecular Therapeutics Program of the Core Cancer Center Grant of Karmanos Cancer Institute before joining University of Michigan. I was also the site PI for the NO1 grant awarded to the California Cancer Consortium. Subsequently, I was co-leader of the Thoracic Oncology Research Program and the Mary Lou Kennedy Research Professor in Thoracic Oncology at the University of Michigan. My clinical research experience spans 20 years. I enrolled about 60 lung cancer patients on clinical trials in 2019 University of Michigan. I am also a member of the steering Committees of the Lung Cancer Committee of Southwest Oncology Group (SWOG). I am a member of the Editorial Board of Clinical Lung Cancer and Cancer and a reviewer for many journals including New England Journal of Medicine, Journal od Clinical Oncology, Lancet Oncology and Journal of Thoracic Oncology. I have also served as faculty for the annual meeting of the American Society of Clinical Oncology (ASCO) and as a member of the Education Committee of ASCO. I am a member of the Communications Committee of the International Association of Study of Lung Cancer (IASLC). I was awarded by the NCI the Cancer Clinical Investigator Team Leadership Award in 2012.

Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Associate Member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Director of Clinical Research for lung cancer, mesothelioma, and other thoracic cancers at Johns Hopkins. He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for earlier stage lung cancer and his work has led to the development of several ongoing phase 3 trials. He leads several international phase 2 and 3 clinical trials of novel immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America while also serving as principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins. He is focused on providing compassionate, state of the art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners and dedicated staff.

Dr. Edelman received his B.S. and M.D. in 1982 as part of the Rensselaer Polytechnic Institute/ Albany Medical College 6 year B.S./M.D. program and performed his residency in Internal Medicine and Fellowship in Hematology/Oncology at the Naval Medical Center San Diego.   He joined the faculty at the University of California, Davis in 1990, where he was co-leader of the thoracic oncology program.  In 1999 he went to the University of Maryland and in 2017, he moved to Fox Chase Cancer Center to become the G. Morris Dorrance Professor and Chair of the Department of Hematology/Oncology and Deputy Director for Clinical Research.  He completed  Naval service with the rank of Captain in 2004. He is medical oncology co-chair for the Lung Cancer Committee of NRG and a member of the ECOG Lung Cancer Committee and a member of the  NCI Thoracic Malignancies Steering Committee. He has served as the Chair of the Integration Panel for the DOD Congressionally Mandated Research Program (lung cancer), and on the ASCO program, education and governmental affairs committees.  He been a member and/or chair of several IASLC committees and a Deputy Editor of “Lung Cancer” and is the Chair of the Scientific Advisory Board for the LCFA.

Dr. Durm is an Indiana native and received his medical degree from the University of Michigan. He completed his residency in internal medicine and fellowship in hematology and oncology at Indiana University. Dr. Durm is an assistant professor of clinical medicine in medical oncology at the Indiana University Simon Comprehensive Cancer Center. His areas of interest include both lung and head and neck malignancies, and he is involved in clinical and translational research. He is also part of the phase I trial program.